These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28677577)

  • 21. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
    van Essen M; Krenning EP; Kam BL; de Herder WW; van Aken MO; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):743-8. PubMed ID: 18188559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted radionuclide therapies for pancreatic cancer.
    Shah M; Da Silva R; Gravekamp C; Libutti SK; Abraham T; Dadachova E
    Cancer Gene Ther; 2015 Aug; 22(8):375-9. PubMed ID: 26227823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of radiolabelled somatostatin analogues (
    Medina-Ornelas SS; García-Pérez FO
    Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Jul; 40(7):564-6. PubMed ID: 25546192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidance on
    Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
    J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment with
    Estorch M
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
    Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G
    Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
    Bomanji JB; Papathanasiou ND
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
    Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radionuclide Therapies in Molecular Imaging and Precision Medicine.
    Kendi AT; Moncayo VM; Nye JA; Galt JR; Halkar R; Schuster DM
    PET Clin; 2017 Jan; 12(1):93-103. PubMed ID: 27863570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The radiobiology of targeted radiotherapy.
    Wheldon TE; O'Donoghue JA
    Int J Radiat Biol; 1990 Jul; 58(1):1-21. PubMed ID: 1973428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules.
    Bushnell D
    J Natl Compr Canc Netw; 2009 Jul; 7(7):760-4. PubMed ID: 19635228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
    Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
    J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
    Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.